ASP2138

ASP2138 is a bispecific antibody developed by Astellas Pharma Global Development. Its targets are Claudin 18.2 and CD3 (the sponsor names CLDN18.2 x CD3). The sponsor states: Binds CLDN18.2 (claudin 18.2) on tumour cells and CD3 on T cells, bringing T cells into proximity with CLDN18.2-expressing tumour cells to activate an anti-tumour T-cell response; administered subcutaneously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07673887 (A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer), in gastric & gastro-oesophageal junction cancer. The largest, NCT07673887, plans to enrol 570 participants with primary completion expected 2031-02-28. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.